Julia Moore

Vitra Labs is a venture-backed biotech startup whose mission is to curb the rise in infertility by making IVF accessible to everyone. Our process aims to recapitulate oogenesis completely in vitro, without using ovarian donor tissue.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOnes ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com

Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.

Based in Boston, MA, STRM.BIO (“storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.

Checkerspot is a biotechnology company designs materials and ingredients at a molecular level to enable more sustainable and high-performing products. By optimizing microalgae, Checkerspot’s vertically integrated WING™ Platform biomanufactures unique oils that are designed to not only replace commodity oils and petroleum-based inputs, but also improve performance properties in targeted hardgoods, textiles, and personal care products. Checkerspot continues to develop new biotech innovations and expand the reach of its commercialized next-generation polyurethanes and algae-derived materials to improve the performance and sustainability of consumer products.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

Vitra Labs is a venture-backed biotech startup whose mission is to curb the rise in infertility by making IVF accessible to everyone. Our process aims to recapitulate oogenesis completely in vitro, without using ovarian donor tissue.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOnes ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com

Breakout Ventures is the home for creative bioscience entrepreneurs. We invest in early stage companies harnessing the power of cells to build solutions in human health and sustainability. Our team has spent the last decade supporting science-driven companies moving with urgency. We partner with bold founders throughout the entire life cycle, from seed to scale. Our portfolio has grown leather without the cow, reprogrammed B cells to produce personalized protein therapeutics, and transformed industrial carbon dioxide emissions into useful products. We believe cells are the engine of the next decade as the tools, technologies and, most importantly, talent from across industries are brought to bear on biology and chemistry in surprising ways. Breakout Ventures, building the future powered by science.

Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.